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Abstract
Thyroid malignancies are relatively rare cancer types but have a substantially high
incidence in the group of all endocrine malignancies. Most thyroid cancer patients have
differentiated thyroid cancer and prognosis is generally favourable. Tumour growth
tends to be slow and radioiodine therapy is successful in differentiated cell tumour
type  with  the  ability  to  accumulate  iodine.  So,  where  can  18F-fluorodeoxyglucose
positron emission tomography (FDG PET) imaging be applied? The role of FDG PET
in differentiated thyroid cancer starts with the development of metastatic diseases,
which are not responsive to radioiodine therapy anymore. FDG accumulates in tumour
lesions that are missed by iodine scintigraphy. FDG PET is more sensitive in patients
with  an  aggressive  histological  subtype,  including  Hürthle  cell.  Thyroid  cancer  is
definitely not the role model indication for FDG PET imaging, but for the manage‐
ment of differentiated thyroid cancer with metastases and more aggressive types of
malignancies  of  the  thyroid,  FDG  PET  proves  to  be  clinically  useful.  Incidental
detection of malignancy in FDG-avid thyroid nodules has to be taken into considera‐
tion when FDG PET examinations have been conducted for reasons unrelated to the
thyroid.
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1. Introduction
1.1. Thyroid cancer
Thyroid malignancies are relatively rare cancer types but have a substantially high incidence
in the group of all endocrine malignancies [1]. Most thyroid cancer patients have differentiat‐
ed thyroid cancer (i.e. the papillary and the follicular type), and prognosis is generally favour‐
able [1]. Tumour growth tends to be slow and radioiodine therapy is successful in differentiated
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cell tumour type with the ability to accumulate iodine. Therefore, where can 18F-fluorodeoxy‐
glucose positron emission tomography (FDG PET) imaging be applied?
2. FDG PET in thyroid cancer
In the last two decades, PET and PET/CT have proven to show a substantial diagnostic role in
most human cancer entities. The development was related to FDG, a glucose derivate labelled
with F18, showing avidity in cancer types with high tumour-related metabolism and upregu‐
lation of the glucose transporter system [2]. Imaging with positron emitting isotopes has the
advantage of higher spatial resolution compared to gamma cameras. That enables quantifica‐
tion and hybrid imaging with CT, which provides precise morphological data. However, what
appears to be useful for patients with melanoma or high-grade lymphoma must not be useful
in the case of thyroid cancer. Here, nuclear medicine provides the possibility of specific gamma
camera imaging with iodine 131 (131I) or 123 (123I) and recently also by PET with iodine 124 (124I).
2.1. FDG PET in differentiated thyroid cancer
There exists a consensus that FDG PET has no objective in the primary evaluation of differen‐
tiated thyroid cancer—routine preoperative FDG PET scanning is not recommended by the
American Thyroid Association (ATA) Management Guidelines [3]. A primary cancer lesion of
the thyroid can easily be missed by FDG PET [1, 4]. In general, the suspicion of thyroid
malignancy leads to thyroidectomy and by this to histologically based diagnosis, including
eventually some form of cervical lymph node surgery. If there is some indication, the next step
is to perform radioiodine ablation, which results additionally in providing post-therapeutic
iodine scan images. For the follow-up examinations, thyroglobulin (Tg) is considered a strong
marker of persistent or recurrent disease [5]. The role of FDG PET starts with the development
of metastatic diseases, which are not responsive to radioiodine therapy any more. FDG
accumulates in tumour lesions that are missed by iodine scintigraphy [1, 4]. A German group
of Tübingen explained these findings as early as 1995 [6]. Highly differentiated thyroid cancer
(DTC) cells still express the sodium-iodide symporter (NIS), which enables iodine uptake in
the thyroid. This ability gets lost when cells become less differentiated. On the contrary, FDG
is internalised to the cell by a transporter protein (glut-1), which is overexpressed in malignant
cell types. Inverse alterations of either iodine or FDG uptake in metastases are called the flip-
flop phenomenon. Feine et al. presented a group of 34 patients showing FDG and/or 131I uptake,
30 of whom exhibited the flip-flop phenomenon. Five per cent of the metastases had both FDG
and 131I uptake [4]. Since then, there has been knowledge of the coexistence of functionally
more differentiated tumour cells with retained iodine trapping mechanism and low glucose
metabolism, and more undifferentiated carcinoma cells that have lost their iodine trapping
mechanism and have a high glucose uptake [7].
A meta-analysis by Dong et al. in 2009 covered 571 patients who had recurrent or metastatic
DTC and a radioiodine-negative whole-body scan (WBS) [8]. FDG-PET was proven to be
especially effective in detecting metastases in patients with elevated Tg levels and normal
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radioiodine WBS. A pooled patient-based sensitivity and specificity of about 84% each was
found for FDG PET.
Optimal initial therapy is mandatory for favourable patient outcome, but can only be per‐
formed if all non-avid tumour lesions are known before treatment planning. Rosenbaum-
Krumme et al. found that the TNM stage was changed due to the FDG PET results in 21% of
the patients. The authors concluded that FDG PET in high-risk patients with DTC nowadays
has been established as an initial-staging modality [7] (Figure 1).
Figure 1. A 47-year-old man presented with sensomotoric deficit of the left arm at the Neurological Clinic in Linz
(Austria). Further diagnosis revealed a thyroid malignoma infiltrating the cervical vertebral column and adjacent soft
tissue (as can be seen FDG-avid on FDG PET/CT images). The next step was a combined operation of the malignant
goiter and the tumour masses infiltrating to the bone. As histology still presented papillary differentiation (Ki-67 was
4%), the patient was sent to radioiodine therapy further on.
FDG PET has a high negative-predictive value (NPV) about 90% in DTC patients regarding
recurrence-free follow-up after 3 years. FDG PET should be performed in all high-risk DTC
patients—after the first radioiodine therapy—to improve patient management and risk
stratification [9]. A prognostic relevance of FDG imaging is therefore presumed. Also, the
volume of FDG-positive malignant tissue is of relevance, Wang et al. showed that volumes of
≤125 ml were associated with a 3-year survival of 96% compared to 18% of patients with higher
volumes [10].
Elevated Tg levels are an indicator for FDG-positive lesions [11], but it has been demonstrated
that high Tg levels are not related to FDG positivity alone, but also to iodine positivity [7]. It
was recognised that about 10–15% of patients have elevated serum Tg levels despite negative
iodine WBS [12]. In respect to the clinical value of Tg measurement, it has to be considered
that Tg autoantibodies interfere with the measurement and may mask the presence of recurrent
or metastatic disease [13]. In this condition, patient surveillance is complicated and some of
the restrictions might be overcome with routinely practised FDG PET in this patient group,
additionally to neck ultrasound and other diagnostic modalities provided by nuclear medicine.
In total, ATA guidelines strongly recommend considering FDG PET scanning in high-risk DTC
patients with elevated serum Tg (generally >10 ng/ml) when negative radioiodine imaging is
expressed [3]. As the availability of PET/CT scanners and cyclotrons has become satisfactory
at least in central Europe, we advocate combined imaging with iodine and FDG whenever
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thyroid hormone withdrawal or stimulation with recombinant human thyroid stimulating
hormone (TSH) has been conducted. Although there have been conflicting reports regarding
the additional advantage for FDG PET imaging, a possible modest benefit due to TSH
stimulation can be assumed [11]. Such a procedure has been successfully introduced in our
institutions located in Austria.
2.2. FDG PET in subtypes of DTC and anaplastic thyroid cancer
Aggressive histologic subtypes of thyroid cancer carry a worse prognosis [14]. The clinical
usefulness for FDG-PET may be more robust for Hürthle cell thyroid cancer (3–4% of DTC) as
opposed to papillary and follicular DTC [15]. Generally, FDG PET is more sensitive in patients
with an aggressive histological subtype, including Hürthle cell, but also poorly differentiated
Figure 2. This 72-year-old woman originally presented with multiple lung metastases incidentally detected at the Hos‐
pital of Wels (Austria). The primary tumour was localised in the thyroid gland and histology revealed poorly differen‐
tiated thyroid carcinoma (Ki67 25%, TTF-1 and Tg positive). For post-operative restaging, FDG PET was arranged and
presented multiple metastases of lung, liver and bone.
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carcinoma, tall cell [3] and insular cell variants. Accurate localisation of disease is essential in
Hürthle cell thyroid cancer because surgery and external beam radiation therapy may be
beneficial. Hürthle cell thyroid cancer tends to be FDG-avid and all patients should undergo
FDG PET in the post-operative setting onwards [15].
Poorly differentiated thyroid carcinoma represents a distinct stage in the progression from
well-differentiated to anaplastic carcinoma [14]. When primary dedifferentiation with high
Ki67 values can be observed and especially in the case of anaplastic thyroid cancer (which
represents about 1.5% of all thyroid malignancies), the usefulness of iodine scanning tends to
be low. This emphasises the importance of FDG PET in this setting (Figure 2). Approximately
20–50% of patients with early tumour dissemination are positive for distant metastases [16].
Unfortunately, the relevance for monitoring the disease is limited because of the bad prognosis
of anaplastic thyroid cancer. Anaplastic carcinoma usually shows intense FDG uptake, and in
selected cases FDG PET may be helpful in directing or evaluating treatment [14]. Here, nuclear
medicine can provide somatostatin receptor imaging as well (to evaluate therapeutic options
as radiopeptide therapy [17]), but monitoring the disease would still be the task of FDG PET.
It is worth noting that the role for FDG PET in staging and restaging of primary lymphoma of
the thyroid gland is evidentially present [18].
2.3. FDG PET in medullary thyroid cancer
Medullary thyroid cancer (MTC) is a rare form of thyroid cancer (about 4–5%), descending
from calcitonin-producing C-cells not related to iodine-capture processes and thyroid hor‐
mone production. Ultrasound, serum calcitonin screening, genetics of multiple endocrine
neoplasia (MEN) syndromes, cytology and histology with immunohistochemistry for calcito‐
nin, and various diagnostic tools of radiology play an important role for diagnosis and disease
monitoring.
In regard to nuclear medicine, the impact of FDG and DOPA PET as well as somatostatin
receptor imaging—and the order in which those methods should be applied—is still a matter
of debate.
A PET study may be requested in patients with high serum calcitonin and/or carcinoembryonic
antigen (CEA) levels after surgery. FDG PET is not a meaningful test in patients with low to
moderate calcitonin levels and can occasionally be negative even at very high calcitonin levels
of >1000 pg/ml [14]. Archier et al. recently reported experiences with a relatively large group
of 86 MTC patients. DOPA PET/CT was positive in 65 patients (sensitivity of 76%), and distant
metastatic disease was observed in 29 patients [19]. Beheshti et al. compared FDG and DOPA
PET in the same patients with MTC and showed superiority of DOPA to detect metastases.
However, lymph node metastases, which were only seen on FDG PET, were also described
[20]. We suggest to use DOPA PET on the first run and to save FDG PET imaging for incon‐
clusive or DOPA PET-negative cases. An illustrative case can be seen in Figure 3.
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Figure 3. Medullary thyroid carcinoma was identified in 2008 at a metastatic stage yet. In 2015, the 74-year-old patient
was sent to the University Hospital St. Pölten (Austria) for restaging by L-3,4-Dihydroxyphenylalanin (is an amino
acid) (DOPA) PET (serum calcitonin of >3000 ng/dl). She also presented with diarrhoea as an associated endocrine
symptom. The DOPA PET images revealed inoperability with cervical tumour masses and extensive thoracic lymph
node metastases. The endocrine clinic ameliorated by the use of somatostatin analogues.
3. FDG PET in thyroid incidentalomas
Meanwhile, there are abundant data consisting of patients who underwent FDG PET/CT for
(mostly oncological) reasons unrelated to pathologies. Then, the finding of a focal FDG uptake
in a thyroid nodule generally merits further examination, and thyroid surgery with histological
verification is necessary in many cases. The intensity of FDG uptake measured by SUV
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(standard uptake value) cannot discriminate with certainty benign and malignant thyroid
nodules. The risk to find a malignant entity can be estimated at 25–50%. Of course, these data
depend upon the characteristics of the patient group as age and iodine supply of the home
country are contributing factors. Diffuse-elevated FDG uptake in the thyroid can be found
when Hashimoto´s thyroiditis is present. Focal uptake is limited to nodules of the thyroid. A
prevalence of 1.5–3% for FDG-avid incidentaloma can be expected [21–23].
4. Conclusion
Thyroid cancer is definitely not the role model indication for FDG PET imaging, but for the
management of differentiated thyroid cancer with metastases and more aggressive types of
malignancies of the thyroid, FDG PET proves to be clinically useful. Incidental detection of
malignancy in FDG-avid thyroid nodules has to be taken into consideration when FDG PET
examinations have been conducted for reasons unrelated to the thyroid.
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